About
Technology
Issues
FAQ
Links
Official Page
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.